BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
28. August 2024 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
Bioatla Reports Second Quarter 2024 Financial Results and Highlights Recent Progress
08. August 2024 16:05 ET
|
BioAtla, Inc.
Ozuriftamab vedotin (CAB-ROR2-ADC) granted Fast Track Designation by FDA in squamous cell carcinoma of the head and neck (SCCHN); anticipate FDA meeting for SCCHN potential registrational trial in 2H...
BioAtla to Announce Second Quarter 2024 Financial Results and Provide Business Highlights on August 8, 2024
01. August 2024 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day
25. Juli 2024 17:39 ET
|
BioAtla, Inc.
Clinical benefit observed among non-small cell lung cancer (NSCLC) patients harboring mutant KRAS (mKRAS) variants in the Phase 2 mecbotamab vedotin (CAB-AXL-ADC) study; AXL tumoral expression highly...
BioAtla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (CAB-ROR2-ADC) for Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
23. Juli 2024 08:00 ET
|
BioAtla, Inc.
Ozuriftamab vedotin, the Company’s conditionally and reversibly active antibody drug conjugate directed against ROR2, has shown promising clinical activity with a manageable safety profile in...
BioAtla to Host Virtual R&D Day on Clinical Program and Pipeline Updates on July 25, 2024
27. Juni 2024 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla to Participate in the Jefferies Global Healthcare Conference
29. Mai 2024 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
23. Mai 2024 17:05 ET
|
BioAtla, Inc.
Multiple refractory PD1 failure patients experienced prolonged progression free survival (10 months ongoing); confirmed responses observed in patients receiving evalstotug High doses of evalstotug as...
BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress
14. Mai 2024 16:05 ET
|
BioAtla, Inc.
Ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 data in squamous cell carcinoma of the head and neck (SCCHN) showed multiple confirmed responses and manageable safety profile; anticipate FDA meeting for...
BioAtla to Participate in the Citizens JMP Life Sciences Conference
08. Mai 2024 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...